• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Kinetics of hydralazine elimination.

作者信息

Talseth T

出版信息

Clin Pharmacol Ther. 1977 Jun;21(6):715-20. doi: 10.1002/cpt1977216715.

DOI:10.1002/cpt1977216715
PMID:862310
Abstract

Hydralazine was given orally in single doses of 10, 25, and 50 mg to 2 slow-acetylating subjects, while 2 rapid-acetylating subjects also received 100- and 150-mg doses on different occasions. Administration of the 50-mg dose to the subjects who were slow acetylators and the 150-mg dose to those who were rapid acetylators caused a disproportionately large increase in the amount of unchanged drug appearing in the systemic circulation as judged from the increases in the ratios of areas under concentration-time curves (AUC) to dose. A modification of the gas-liquid chromatographic hydralazine assay allowed the simultaneous determination of hydralazine and its acetylated metabolite, 3-methyl-s-triazolo-3,4,a-phthalazine (MTP), in serum. It was found that the disproportionately large increases in the AUC/dose ratio of hydralazine upon intake of 50 or 150-mg doses by the slow and rapid-acetylating subjects, respectively, were paralleled by a decrease in the ratio AUCMTP/AUChydralazine during a 6-hr observation period. It is concluded that the acetylation of hydralazine in man is a capacity-limited process.

摘要

相似文献

1
Kinetics of hydralazine elimination.
Clin Pharmacol Ther. 1977 Jun;21(6):715-20. doi: 10.1002/cpt1977216715.
2
Gas chromatographic method for the simultaneous determination of hydralazine and its acetylated metabolite in serum using a nitrogen-selective detector.
J Chromatogr. 1980 Aug 8;183(2):159-66. doi: 10.1016/s0378-4347(00)81689-8.
3
Studies on hydralazine. III. Bioavailability of hydralazine in man.
Eur J Clin Pharmacol. 1976;10(6):395-401. doi: 10.1007/BF00563075.
4
Polymorphic acetylation of hydralazine.
Clin Pharmacol Ther. 1980 Sep;28(3):350-5. doi: 10.1038/clpt.1980.173.
5
Selective high-performance liquid chromatographic assays for hydralazine and its metabolites in plasma of man.
J Chromatogr. 1980 Mar 14;181(3-4):427-40. doi: 10.1016/s0378-4347(00)81145-7.
6
Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.
J Pharmacokinet Biopharm. 1980 Feb;8(1):53-68. doi: 10.1007/BF01059448.
7
Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man.关于人体内肼屈嗪代谢中乙酰化表型差异的进一步证据。
Br J Clin Pharmacol. 1981 Apr;11(4):345-51. doi: 10.1111/j.1365-2125.1981.tb01131.x.
8
The determination of hydralazine in plasma by gas-liquid chromatography.
J Chromatogr. 1975 Dec 10;115(1):87-92. doi: 10.1016/s0021-9673(00)89019-6.
9
Hydralazine kinetics after single and repeated oral doses.
Clin Pharmacol Ther. 1980 Dec;28(6):804-11. doi: 10.1038/clpt.1980.238.
10
Effect of oral dose size on hydralazine kinetics and vasodepressor response.口服剂量大小对肼屈嗪动力学和血管减压反应的影响。
Clin Pharmacol Ther. 1984 Nov;36(5):595-600. doi: 10.1038/clpt.1984.227.

引用本文的文献

1
Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues.特异质性药物性肝损伤(DILI)的机制:尚未解决的基本问题。
Ann Transl Med. 2021 Apr;9(8):730. doi: 10.21037/atm-2020-ubih-05.
2
Effect of N-Acetyltransferase 2 Genotype on the Pharmacokinetics of Hydralazine During Pregnancy.乙酰转移酶 2 基因型对妊娠期肼屈嗪药代动力学的影响。
J Clin Pharmacol. 2019 Dec;59(12):1678-1689. doi: 10.1002/jcph.1477. Epub 2019 Jun 30.
3
Pharmacologic treatment of chronic pediatric hypertension.儿童慢性高血压的药物治疗
Paediatr Drugs. 2005;7(1):27-40. doi: 10.2165/00148581-200507010-00003.
4
Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.
J Pharmacokinet Biopharm. 1980 Feb;8(1):53-68. doi: 10.1007/BF01059448.
5
Effects of concurrent administration of other substrates of N-acetyltransferase on dapsone acetylation.同时给予N-乙酰转移酶的其他底物对氨苯砜乙酰化的影响。
Br J Clin Pharmacol. 1981 Jul;12(1):83-6. doi: 10.1111/j.1365-2125.1981.tb01860.x.
6
Clinical pharmacokinetics of hydralazine.肼屈嗪的临床药代动力学。
Clin Pharmacokinet. 1982 May-Jun;7(3):185-205. doi: 10.2165/00003088-198207030-00001.
7
Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure.肼屈嗪在充血性心力衰竭中的临床药代动力学及治疗应用
Clin Pharmacokinet. 1989 Feb;16(2):86-9. doi: 10.2165/00003088-198916020-00003.
8
Clinical pharmacokinetics of hydrallazine.
Clin Pharmacokinet. 1977 Sep-Oct;2(5):317-29. doi: 10.2165/00003088-197702050-00001.